FollowPlay Earnings CallPlay Earnings Call
Biogen Inc. (NASDAQ:BIIB) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDT
Company Participants
Priya Singhal – Executive VP & Head of Development
Conference Call Participants
William Pickering – Sanford C. Bernstein & Co., LLC., Research Division
Presentation
William Pickering
Sanford C. Bernstein & Co., LLC., Research Division
Welcome, everyone. My name is Will Pickering. I’m Bernstein’s analyst for U.S. Biotech. Very pleased to have Biogen here today joined by Priya Singhal, Head of Development. Priya, thank you so much for coming.
Priya singhal
Executive VP & Head of Development
Thank you for having me.
Question-and-Answer Session
William Pickering
Sanford C. Bernstein & Co., LLC., Research Division
In many ways, I think that Biogen needs no introduction. It’s a long well-known company in our industry, but — maybe you could take a few moments to speak to the journey that you’ve been on to create a new Biogen, how your approach to R&D is evolving?
Priya singhal
Executive VP & Head of Development
Yes, we’ve been very excited to create the new Biogen. And I’m really pleased because I think we are well on our way. And I’ll start with the fact that from a commercial perspective, the Alzheimer’s launch, we are seeing some inflection points in the LEQEMBI launch. This is important because we just got approval for subcutaneous maintenance, which we think is a very important option for patients. And we’ve also begun our rolling submission for the subcutaneous initiation. That means patients, hopefully, once we have the outcome next year for subcutaneous initiation and we already have it for maintenance, patients could actually have an autoinjector that they take at home. And I think it provides optionality because they can still choose to come to an infusion center, and we know there are many different segments of patients as well as health care providers.
GIPHY App Key not set. Please check settings